Working... Menu

MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion in Patients With Incurable MAGE-A3-Expressing Solid Tumours (I214)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02285816
Recruitment Status : Active, not recruiting
First Posted : November 7, 2014
Last Update Posted : July 15, 2019
Ottawa Hospital Research Institute
Information provided by (Responsible Party):
Canadian Cancer Trials Group